Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms (Q40560857)

21 September 2017

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms (English)

1 reference

21 September 2017

1 reference

Hongbo Zhu

1

1 reference

21 September 2017

Lidong Zhang

2

1 reference

21 September 2017

Xuefeng Huang

3

1 reference

21 September 2017

John J Davis

4

1 reference

21 September 2017

Dietmar A Jacob

5

1 reference

21 September 2017

Fuminori Teraishi

6

1 reference

21 September 2017

Paul Chiao

7

1 reference

21 September 2017

Bingliang Fang

8

1 reference

21 September 2017

1 May 2004

1 reference

21 September 2017

1 reference

21 September 2017

9

1 reference

21 September 2017

5

1 reference

21 September 2017

666-673

1 reference

Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Safety and antitumor activity of recombinant soluble Apo2 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Regulation of TRAIL-induced apoptosis by transcription factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Bax directly induces release of cytochrome c from isolated mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

5-Fluorouracil suppression of NF-KappaB is mediated by the inhibition of IKappab kinase activity in human salivary gland cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.02.007

10.1016/J.YMTHE.2004.02.007

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference